 Home > Active Ingredient News > Blood System > LEUKEMIA: Poor results of COVID-19 patients after CAR T cell treatment of B-cell malignancies

LEUKEMIA: Poor results of COVID-19 patients after CAR T cell treatment of B-cell malignancies

 Last Update: 2021-12-01
 Source: Internet
 Author: User

Tags

geo group jobs

cell differentiation examples

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

For hematopoietic stem cell transplantation (HCT) recipients and patients with hematological malignancies, COVID-19 causes severe morbidity and mortality compared to the general population

Illness duration is defined as the time from diagnosis of COVID-19 to resolution of the disease, defined as a negative PCR test or regression or death based on clinical findings

A total of 57 patients from 11 countries were reported to EBMT.

At the time of analysis, 25 of 56 patients (44.

Figure 1: The overall survival rate of patients after COVID-19 diagnosis

The results show that patients diagnosed with COVID-19 after receiving B-cell targeted CAR-T cell therapy have a very poor prognosis, and it is essential to prevent the spread of SARS-CoV-2 and disease development in CAR-T cell recipients

The cell response results of this group to vaccination are currently lacking

Spanjaart, AM, Ljungman, P.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.